Themis Medicare (BOM:530199) ROCE %: 10.89% (As of Mar. 2026)

What is Themis Medicare ROCE %?

Themis Medicare BOM:530199 +1.19% 69 ROCE % is 10.89% as of Mar. 2026. GuruFocus rates BOM:530199 with a GF Score™ of 69/100 and a GF Value™ of ₹149.07 (Modestly Undervalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Themis Medicare's annualized ROCE % for the quarter that ended in Mar. 2026 was 10.89%.

Themis Medicare (BOM:530199) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Themis Medicare ROCE % Related Terms

Themis Medicare ROCE % Historical Data

* Premium members only.

The historical data trend for Themis Medicare's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Themis Medicare ROCE % Chart

Themis Medicare Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

ROCE %

Get a 7-Day Free Trial

36.29

23.23

15.50

11.76

2.92

Themis Medicare Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															-8.04	-10.74	-0.67	12.86	10.89

69GF Score

Themis Medicare Ltd BOM:530199

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Themis Medicare ROCE % Calculation

Themis Medicare's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2026 )		(A: Mar. 2025 )		(A: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2026 )		(A: Mar. 2025 )		(A: Mar. 2026 )
	=	126.168	/	( ( (5880.318 - 1561.246)	+	(5979.079 - 1661.596) )	/ 2 )
	=	126.168	/	( (4319.072	+	4317.483)	/ 2 )
	=	126.168	/	4318.2775
	=	2.92 %

Themis Medicare's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	470.376	/	( ( (0 - 0)	+	(5979.079 - 1661.596) )	/ 1 )
	=	470.376	/	( ( 0	+	4317.483 )	/ 1 )
	=	470.376	/	4317.483
	=	10.89 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 10.89% mean?

Themis Medicare (BOM:530199) has a ROCE % of 10.89% as of Mar. 2026.

Is Themis Medicare's ROCE % too high?

Themis Medicare's current ROCE % is 10.89%. The Drug Manufacturers industry median ROCE % is 7.03. Themis Medicare's value of 10.89% is 54.9% above this industry median. Overall, Themis Medicare has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.

How does Themis Medicare's ROCE % compare to ZTS and UTHR?

Themis Medicare's ROCE % of 10.89% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.03. Themis Medicare's value of 10.89% is 54.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Drug Manufacturers company?

The median ROCE % among Drug Manufacturers companies is 7.03, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Themis Medicare's current ROCE % of 10.89% is 54.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Themis Medicare's current ROCE % is 10.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Themis Medicare stock overvalued right now?

Based on GuruFocus' analysis, Themis Medicare (BOM:530199) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹149.07, compared to a current price of ₹110.60 — trading 25.8% below its estimated fair value. The current ROCE % is 10.89% and 54.9% above the Drug Manufacturers industry median of 7.03. Themis Medicare's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Themis Medicare (BOM:530199), the current ROCE % is 10.89% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Themis Medicare (BOM:530199) Overvalued in 2026?

Based on GuruFocus' analysis, Themis Medicare stock appears to be undervalued. The current stock price of ₹110.60 is trading 25.8% below its estimated GF Value™ of ₹149.07. GuruFocus considers Themis Medicare to be Modestly Undervalued.

Key valuation signals for BOM:530199:

ROCE %: 10.89%
GF Value™: ₹149.07 vs. price of ₹110.60 (25.8% below fair value)
GF Score™: 69/100 with 6 warning signs
Industry Position: 54.9% above the Drug Manufacturers median

No single metric tells the full story. See the BOM:530199 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Themis Medicare Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies BOM:506414 BOM:539872 NSE:ACCENTMIC BOM:524212 BOM:543389 BOM:541096 BOM:540737 NSE:AHCL BOM:531633 BOM:524632 XTER:MRK XSWX:GALD TSE:4502 SHSE:600276 NSE:SUNPHARMA LSE:HLN XTAE:TEVA XSWX:SDZ ZTS UTHR

Other Exchanges THEMISMED:India

Address Swami Vivekanand Road, 11/12, Udyog Nagar Industrial Estate, Goregaon (West), Mumbai, MH, IND, 400 104

Website https://www.themismedicare.com

Themis Medicare Ltd is an Indian based company engaged in the manufacturing and marketing of pharmaceutical products. The Company operates only in one business segment which is Pharmaceuticals. Geographically, it derives a majority of revenue from India and also has a presence in the international market. Its product categories include Anti Malarial, CCD products, Nutritional Gummies, and Candy and Other Products such as OD-LM, Dexem, Medzol and Tazowin.

69GF Score

Get the complete analysis for BOM:530199

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹110.60

Price

₹149.07

GF Value

View BOM:530199 Analysis

See ROCE % data for all stocks →